問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of General Internal Medicine

更新時間：2023-09-19

李承翰
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李承翰

List

4Cases

2017-09-01 - 2019-01-03

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated7Sites

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

2017-03-17 - 2023-03-17

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    Selonsertib

Participate Sites
5Sites

Terminated4Sites

黃志富
Kaohsiung Municipal Gangshan Hospital

未分科

沈一嫻
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2017-03-03 - 2023-02-28

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

  • Condition/Disease

    Nonalcoholic Steatohepatitis(NASH)

  • Test Drug

    Selonsertib

Participate Sites
20Sites

Terminated18Sites

黃志富
Kaohsiung Municipal Gangshan Hospital

未分科

沈一嫻
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2017-05-01 - 2025-12-31

Others

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    CVC /150mg tablet

Participate Sites
13Sites

Not yet recruiting9Sites

Recruiting1Sites

Terminated1Sites

彭成元
China Medical University Hospital-Taipei

未分科

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB